LENZ
LENZ Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.85
+0.34%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$183.81M
MomentumView details →
1D Return
+0.34%
YTD Return
−63.87%
RSI (14)
63.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
Market Cap
$183.81M
RSI (14)
63.8
MomentumView details →
1D Return
+0.34%
YTD Return
−63.87%
SummaryUpdated Jun 1, 2026
LENZ Therapeutics, Inc. (NASDAQ:LENZ) is a clinical-stage biopharmaceutical company founded to develop innovative treatments for presbyopia, a common age-related vision condition. The company went public in March 2024 and is headquartered in Del Mar, California. LENZ is currently preparing for the potential commercial launch of its lead product candidate LNZ100, which has completed Phase III clinical trials and has a pending New Drug Application (NDA) with the FDA, with a target approval date of August 8, 2025.
Similar companies
Latest newsMore news →
LENZ Therapeutics reported its second quarter 2026 financial results, with total revenue of $5.5 million from VIZZ product sales and global license agreements.24d agoLENZ Therapeutics launched a new telehealth prescribing option for VIZZ to treat presbyopia.60d agoLENZ Therapeutics and Arrotex Pharmaceuticals entered into an exclusive license and commercialization agreement for VIZZ in Australia and New Zealand.72d ago